BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E514.81 EPS (ttm)0.15 Insider Own0.50% Shs Outstand183.99M Perf Week3.80%
Market Cap14.41B Forward P/E31.70 EPS next Y2.50 Insider Trans-18.25% Shs Float182.79M Perf Month-1.65%
Income35.40M PEG16.01 EPS next Q0.11 Inst Own99.20% Short Float6.22% Perf Quarter-12.20%
Sales1.88B P/S7.67 EPS this Y-107.90% Inst Trans1.27% Short Ratio8.78 Perf Half Y-1.81%
Book/sh23.87 P/B3.32 EPS next Y216.98% ROA0.70% Target Price116.39 Perf Year0.20%
Cash/sh5.81 P/C13.64 EPS next 5Y32.16% ROE0.90% 52W Range71.59 - 94.20 Perf YTD-10.27%
Dividend- P/FCF308.60 EPS past 5Y37.20% ROI-1.40% 52W High-15.84% Beta0.43
Dividend %- Quick Ratio3.30 Sales past 5Y10.60% Gross Margin75.10% 52W Low10.74% ATR2.71
Employees3045 Current Ratio4.90 Sales Q/Q6.90% Oper. Margin1.60% RSI (14)49.12 Volatility2.62% 3.44%
OptionableYes Debt/Eq0.00 EPS Q/Q557.90% Profit Margin2.10% Rel Volume0.66 Prev Close78.18
ShortableYes LT Debt/Eq0.25 EarningsApr 27 AMC Payout0.00% Avg Volume1.30M Price79.28
Recom1.70 SMA20-0.75% SMA50-1.10% SMA200-2.94% Volume851,209 Change1.41%
Apr-25-22Upgrade Morgan Stanley Equal-Weight → Overweight $96 → $113
Nov-22-21Upgrade William Blair Mkt Perform → Outperform
Oct-07-21Resumed Jefferies Buy $100
Sep-09-21Upgrade Stifel Hold → Buy $86 → $96
Jun-04-21Resumed Robert W. Baird Outperform $101
Apr-26-21Resumed Credit Suisse Outperform $102
Mar-04-21Resumed Guggenheim Buy
Mar-01-21Upgrade Evercore ISI In-line → Outperform $90 → $100
Aug-20-20Downgrade William Blair Outperform → Mkt Perform
Aug-20-20Downgrade Citigroup Buy → Neutral $148 → $86
Aug-19-20Downgrade Stifel Buy → Hold $127 → $100
Aug-19-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-19-20Downgrade Evercore ISI Outperform → In-line
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $125
Jul-06-20Reiterated Citigroup Buy $105 → $148
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Jan-24-20Upgrade RBC Capital Mkts Sector Perform → Outperform $111 → $113
Nov-27-19Upgrade Barclays Equal Weight → Overweight $86 → $98
Nov-12-19Initiated SunTrust Buy $110
May-11-22 07:32AM  
May-05-22 04:04PM  
08:29AM  
May-04-22 09:00AM  
May-02-22 11:04AM  
08:34AM  
Apr-29-22 12:33PM  
Apr-28-22 02:35PM  
12:30PM  
Apr-27-22 05:25PM  
04:02PM  
Apr-26-22 11:44AM  
Apr-13-22 09:00AM  
Mar-25-22 11:30AM  
Mar-17-22 08:31AM  
Mar-10-22 10:26AM  
Feb-24-22 05:09PM  
10:50AM  
Feb-23-22 05:25PM  
04:03PM  
Feb-22-22 12:01PM  
Feb-18-22 04:02PM  
08:44AM  
Feb-17-22 04:05PM  
Feb-16-22 04:00PM  
Feb-10-22 09:00AM  
Feb-09-22 08:31AM  
Feb-08-22 02:38PM  
Feb-07-22 06:38PM  
09:38AM  
Feb-06-22 03:27PM  
Feb-04-22 11:15AM  
Feb-03-22 06:24PM  
Feb-02-22 04:04PM  
01:38PM  
Jan-28-22 12:47PM  
Jan-26-22 09:38AM  
Jan-20-22 09:38AM  
Jan-19-22 09:38AM  
08:56AM  
Jan-14-22 04:51PM  
Jan-12-22 11:10AM  
03:48AM  
Jan-10-22 08:34AM  
07:55AM  
06:29AM  
Jan-09-22 03:13PM  
Jan-04-22 05:08PM  
06:00AM  
Dec-31-21 06:18PM  
Dec-30-21 06:01PM  
06:52AM  
Dec-29-21 06:01PM  
Dec-28-21 05:49PM  
Dec-27-21 09:38PM  
Dec-24-21 06:18PM  
Dec-22-21 08:42PM  
06:15PM  
04:20PM  
04:00PM  
11:00AM  
Dec-21-21 10:01PM  
06:38PM  
01:40PM  
01:16PM  
01:00PM  
11:43AM  
08:00AM  
Dec-20-21 05:29PM  
02:28PM  
10:04AM  
09:50AM  
07:45AM  
Dec-19-21 09:36PM  
08:24AM  
Dec-18-21 10:15AM  
Dec-17-21 06:18PM  
05:38PM  
04:10PM  
12:00PM  
08:00AM  
Dec-16-21 07:30PM  
04:27PM  
04:05PM  
04:00PM  
12:35PM  
09:55AM  
04:04AM  
Dec-15-21 09:57PM  
07:20PM  
06:15PM  
04:05PM  
01:20PM  
07:45AM  
Dec-14-21 10:09PM  
09:00PM  
08:08PM  
10:00AM  
09:40AM  
07:45AM  
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerMay 06Option Exercise37.4620,000749,200355,324May 09 09:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 06Sale81.0020,0001,620,000335,324May 09 09:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Option Exercise37.4610,000374,600345,324May 09 09:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Sale84.1410,000841,400335,324May 09 09:29 PM
Mueller BrianEVP, Chief Financial OfficerMay 04Option Exercise37.4611,800442,02848,401May 06 07:45 PM
Mueller BrianEVP, Chief Financial OfficerMay 04Sale84.5011,800997,10038,639May 06 07:45 PM
Davis George EricEVP, Chief Legal OfficerMay 02Option Exercise37.4615,347574,89981,686May 04 12:01 PM
MEIER RICHARD ADirectorMay 02Option Exercise37.468,500318,410107,892May 04 12:21 PM
Davis George EricEVP, Chief Legal OfficerMay 02Sale80.3815,3471,233,59266,339May 04 12:01 PM
MEIER RICHARD ADirectorMay 02Sale82.093,878318,345104,014May 04 12:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 29Option Exercise37.465,000187,300339,983May 02 09:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 29Sale81.955,000409,750334,983May 02 09:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 28Option Exercise37.4620,000749,200354,983May 02 09:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 28Sale83.7920,0001,675,800334,983May 02 09:27 PM
Davis George EricEVP, Chief Legal OfficerApr 25Option Exercise37.462,66999,98165,998Apr 27 08:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 18Option Exercise37.4620,000749,200354,983Apr 20 08:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 18Sale81.9120,0001,638,200334,983Apr 20 08:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 14Option Exercise37.4610,000374,600344,983Apr 18 09:46 PM
LAWLIS V BRYANDirectorApr 14Option Exercise37.464,250159,20528,220Apr 18 08:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 14Sale83.6610,000836,600334,983Apr 18 09:46 PM
LAWLIS V BRYANDirectorApr 14Sale83.664,250355,55523,970Apr 18 08:22 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 13Sale82.471,18097,31555,077Apr 14 07:54 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 30Sale79.561,381109,87256,257Mar 31 09:28 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 29Sale79.431,618128,51857,638Mar 31 09:28 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 23Sale81.786,129501,23059,256Mar 24 08:49 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 22Sale81.002,073167,91365,385Mar 24 08:49 PM
Davis George EricEVP, General CounselMar 21Sale81.296,129498,22663,329Mar 23 09:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Option Exercise37.4615,000561,900353,569Mar 14 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Sale77.8115,0001,167,150338,569Mar 14 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Option Exercise37.4615,000561,900353,569Mar 14 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale77.5715,0001,163,550338,569Mar 14 08:44 PM
Slamon DennisDirectorFeb 28Sale78.336,396501,01321,639Mar 02 04:57 PM
HERON ELAINE JDirectorFeb 25Option Exercise37.468,500318,41080,588Feb 28 09:52 PM
LAWLIS V BRYANDirectorJan 14Option Exercise37.464,250159,20528,220Jan 19 06:34 PM
LAWLIS V BRYANDirectorJan 14Sale87.614,250372,34223,970Jan 19 06:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 13Option Exercise37.465,000187,300308,789Jan 14 08:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 13Sale87.865,000439,300303,789Jan 14 08:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 12Option Exercise37.465,000187,300308,789Jan 14 08:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 12Sale89.005,000445,000303,789Jan 14 08:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 16Option Exercise37.466,000224,760309,689Dec 17 07:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 16Sale84.686,000508,080303,689Dec 17 07:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 15Option Exercise37.466,000224,760309,689Dec 17 07:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 15Sale82.716,000496,260303,689Dec 17 07:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 01Sale87.221,500130,832304,389Dec 02 09:42 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerOct 26Sale73.602,739201,59055,853Oct 28 07:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 20Option Exercise37.461,00037,460305,839Oct 22 04:36 PM
Davis George EricEVP, General CounselAug 02Sale76.695,518423,17558,590Aug 04 04:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 21Option Exercise37.461,00037,460304,839Jun 23 05:04 PM